ImmuCell Corporation (NASDAQ:ICCC – Get Free Report) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totaling 10,435 shares, a decrease of 42.6% from the April 30th total of 18,194 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average daily volume of 27,303 shares, the days-to-cover ratio is currently 0.4 days.
ImmuCell Stock Down 1.6%
Shares of ImmuCell stock traded down $0.16 during trading on Thursday, reaching $9.89. The company had a trading volume of 3,067 shares, compared to its average volume of 22,819. The company has a market cap of $89.47 million, a price-to-earnings ratio of -164.81 and a beta of 0.55. The firm’s fifty day moving average is $8.21 and its 200-day moving average is $6.81. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.60 and a current ratio of 4.82. ImmuCell has a fifty-two week low of $4.52 and a fifty-two week high of $10.75.
ImmuCell (NASDAQ:ICCC – Get Free Report) last issued its earnings results on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.16. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%. The business had revenue of $10.36 million for the quarter, compared to analyst estimates of $5.40 million.
Wall Street Analyst Weigh In
View Our Latest Stock Report on ICCC
Institutional Investors Weigh In On ImmuCell
A number of institutional investors have recently modified their holdings of ICCC. Geode Capital Management LLC grew its position in shares of ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 2,907 shares during the last quarter. Steadtrust LLC bought a new stake in shares of ImmuCell during the 3rd quarter valued at about $198,000. Mesirow Financial Investment Management Inc. grew its position in shares of ImmuCell by 199.6% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after buying an additional 24,303 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of ImmuCell by 3.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 1,749 shares during the last quarter. Finally, Militia Capital Management LLC bought a new stake in shares of ImmuCell during the 1st quarter valued at about $114,000. Institutional investors own 13.47% of the company’s stock.
About ImmuCell
ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.
The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.
Featured Stories
- Five stocks we like better than ImmuCell
- The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker
- Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
- Gen Z Trends Make These 3 Stocks Worth Watching
- How the Memory Shortage Is Crushing the Gaming Industry
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.
